Personal bionics maker BiOM may eventually take its case to the public markets, eyeing a potential initial public offering, according to a report in the Boston Business Journal.
BiOM has raised $6 million through a debt and equity financing, according to regulatory filing with the Federal Securities and Exchange Commission.
The Bedford, Mass.-based BiOM (formerly known as iWalk) listed 18 investors in the Dec. 23rd filing, including an unnamed "non-U.S. purchaser." which invested a total of $1,079,160 into the bionics prosthetics maker. The company is looking to raise up to $10 million in this round.
On July 15, 2014, MassDevice.com brought together 4 senior medtech leaders to discuss the future of the medical device industry at our DeviceTalks Boston event.
A group of medtech insiders gathered in Boston last night to talk shop, share stories and glean insight from some of the industry’s brightest minds at MassDevice’s DeviceTalks East conference.
BiOM has named Dr. Charles Carignan as its next CEO, replacing Tim McCarthy, who left the company this past spring.
Carignan is a 20-year medtech veteran who has held several key positions in the medical device industry, including most recently at NinePoint Medical, where he was the founder and CEO.
A version of this story was originally posted on BetaBoston.com
Shadow Robot Co.’s so-called bionic man is making its way across the world, parading about a $1 million worth of advanced medical prosthetics that allow him to walk, breath and even hold light conversation.
The bionic man, the 1st of his kind, is a composite of parts from various medical device makers, including robotic feet and ankles from Massachusetts-based BiOM, an artificial heart made by Arizona’s SynCardia Systems and a retinal prosthesis from California’s Second Sight Medical.